Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00388362
Status:
COMPLETED
Last Update Posted:
2017-04-21
First Post:
2006-10-12
Brief Title:
Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
A Phase II Trial of Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the effectiveness of an immunosuppressive drug sirolimus in the treatment of chronic graft versus host disease in combination with prednisone
Detailed Description:
The purpose of this trial is to study the effectiveness of an immunosuppressive drug sirolimus in the treatment of chronic graft versus host disease in combination with prednisone Graft versus host disease GVHD is a common complication in patients who have received blood or marrow transplantation from a related or unrelated donor Chronic GVHD occurs approximately 100 days after transplantation and is the result of the donor immune system recognizing the patients tissues as foreign and creating harmful effects on the patients organs We hope the use of sirolimus will decrease the significant disabling effects and deaths caused by chronic GVHD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 96589 | OTHER | None | None |
| BMT175 | OTHER | OnCore Number | None |